Sacubitril/Valsartan Dosing Regimen
Start sacubitril/valsartan at 49/51 mg twice daily in most adult HFrEF patients, then double the dose every 2-4 weeks to reach the target maintenance dose of 97/103 mg twice daily. 1
Standard Adult Dosing Algorithm
Initial Dose Selection
For patients on high-dose ACEi/ARB:
- Start at 49/51 mg twice daily 2
- High-dose defined as: enalapril ≥10 mg daily or valsartan ≥160 mg daily
For patients on low/medium-dose ACEi/ARB, ACEi/ARB-naive, or with specific risk factors:
- Start at 24/26 mg twice daily 2, 1
- Risk factors include:
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Moderate hepatic impairment (Child-Pugh Class B)
- Age ≥75 years
- Not currently on ACEi/ARB
Titration Schedule
Standard uptitration:
- Increase dose every 2-4 weeks as tolerated 1
- Progression: 24/26 mg → 49/51 mg → 97/103 mg (target) twice daily
- Monitor blood pressure, electrolytes, and renal function after each dose change 2
Evidence supports both approaches: The TITRATION trial demonstrated that both condensed (3-week) and conservative (6-week) uptitration regimens were similarly tolerated, though gradual titration maximized target dose attainment in patients on low-dose ACEi/ARB 3. In clinical practice, approximately 76% of patients achieved target dose within 12 weeks 3.
Critical Washout Period
Mandatory 36-hour washout when switching from ACEi to sacubitril/valsartan to prevent angioedema 2, 1. This washout is not required when switching from an ARB 2, 4.
Practical Tip for Hospitalized Patients
Discontinue ACEi at hospital admission to enable sacubitril/valsartan initiation 36 hours later, before discharge 4.
In-Hospital Initiation
For hemodynamically stable hospitalized HFrEF patients (based on PIONEER-HF criteria) 5:
Eligibility requirements:
- Systolic BP ≥100 mm Hg for at least 6 hours
- No increase in diuretic/vasodilator dose for ≥6 hours
- No IV inotropes for 24 hours
- eGFR ≥30 mL/min/1.73 m²
- Potassium ≤5.2 mEq/L
Initial dosing based on blood pressure:
- SBP 100-120 mm Hg: Start 24/26 mg twice daily
- SBP ≥120 mm Hg: Start 49/51 mg twice daily 5
Adjust dose every 1-2 weeks after discharge according to systolic BP 5.
Monitoring Parameters
After initiation or dose increase, assess:
- Blood pressure (watch for hypotension, especially in volume-depleted patients) 2
- Renal function and potassium within 1-2 weeks 2
- For patients with preserved renal function: check at 2-3 days, 7 days, then monthly for 3 months, then every 3 months 2
Dose reduction triggers:
- eGFR decrease >30% from baseline
- Development of hyperkalemia
- Symptomatic hypotension 2
Common Pitfalls to Avoid
Starting too high in vulnerable patients: Always use 24/26 mg twice daily in elderly, renally impaired, or ACEi/ARB-naive patients 2
Inadequate washout from ACEi: The 36-hour period is mandatory and non-negotiable to prevent angioedema 2
Initiating in volume-depleted patients: Up to 25% of PIONEER-HF patients developed hypotension; ensure adequate volume status before initiation 2
Delaying initiation for aldosterone antagonist: Lack of aldosterone antagonist therapy should not delay ARNI initiation 2
Overly aggressive uptitration: While target dose is ideal, real-world data shows only 27% achieve 200 mg twice daily within 6 months 6. Slower titration may improve long-term adherence 3
Target Dose Achievement
The goal is 97/103 mg twice daily (total daily dose 194/206 mg) 7, 8, 1. However, at least 50% of target dose (49/51 mg twice daily) provides meaningful clinical benefit and is considered acceptable when higher doses are not tolerated 7.
Real-world evidence suggests that intermediate doses (49/51 mg or 97/103 mg twice daily) provide substantial benefit compared to very low doses (24/26 mg), with heterogeneous incremental benefit beyond intermediate dosing 9. This supports aggressive uptitration from starting dose to at least 49/51 mg twice daily, with continued attempts to reach target dose as tolerated.